ADMA Biologics Q1 revenue $81.9M (+44% YoY); raises FY2024-25 guidance

ADMA BIOLOGICS, INC.

2024-Q1 EPS reported $0.08 revenue$81,875,000

GAAP net income $17.8M vs net loss of $6.8M in prior year; adjusted EBITDA $26.4M, a 970% increase.
Gross margin improved to 48% from 29% YoY; working capital $223.3M, cash $45.3M.
FY2024 revenue guidance raised to >$355M (prior >$330M); net income >$85M (prior >$65M).
FY2025 revenue guidance raised to >$410M; adjusted EBITDA >$160M, up from >$140M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ADMA BIOLOGICS, INC. reported three months ended March 31, 2024 results: revenue $81.9 Million, net income $17.8 Million. Guidance raised.

Period: three months ended March 31, 2024
Revenue: $81.9 Million
Net income: $17.8 Million
Guidance: raised
Result: reported results

Exact text from the filing

ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update 1Q 2024 Total Revenue of $81.9 Million, a 44% Increase Y-o-Y 1Q 2024 GAAP Net Income of $17.8 Million, a $24.6 Million Increase Y-o-Y

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

ADMA BIOLOGICS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-24-025173

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.